Table 1. Key changes between 2021 and 2014 TPPs for peripheral TB drug-susceptibility testing.

	2014		2021
	Optimal	Minimal	Optimal	Minimal
Goal	Diagnosis of TB disease and detection of drug resistance to inform decision-making about the optimal first-line regimen (HRZE, REMox or PaMZ) for treatment, and possibly to detect the presence of additional resistance to second-line anti-TB agents and the need for further testing		Diagnosis of TB disease and detection of drug resistance to inform decision-making about the optimal (individualised) regimen	Diagnosis of TB disease and detection of drug resistance to provide rapid triage of patients and identification of adequate treatment regimen (first-line treatment versus second-line treatment)
Priority drugs	In order of decreasing importance: 1.RIF 2. FQs (including MFX) 3. INH and PZA (equally important) 4. AGs and CAP Optimally all drugs would be included, but as a minimum at least RIF should be included		In order of decreasing importance: Minimal + 1. PZA + LZD + Pa/DLM + CFZ 2. AMK + DCS 3. Any additional drug listed in the WHO treatment guidelines	RIF + INH+ FQ + BDQ (see explanation on BDQ in the main text) (FQ always includes LFX and MFX)
Target population	Target groups are all patients suspected of having TB, with a special focus on those at high risk of morbidity and mortality from drug-resistant TB, such as people living with HIV and those at high risk of having MDR-TB (for example, household contacts of patients diagnosed with MDR-TB, and persons with a history of TB, especially those for whom first-line therapy has failed) in countries with a medium prevalence to a high prevalence of TB as defined by WHO		People of all ages in need of evaluation for TB and those requiring drug resistance assessment
Sample type	Unprocessed sputum		Unprocessed sputum and additional clinically relevant specimens for TB or other targeted diseases (see “Multi-use platform”)	Sputum and other clinically relevant specimens for TB, including (but not limited to) gastric aspirate, induced sputum, nasopharyngeal aspirate, and stool.

Abbreviations: AGs–aminoglycosides; AMK–amikacin; BDQ–bedaquiline; CAP–capreomycin; CFZ–clofazimine; DCS–D-cycloserine; DLM–delamanid; FQ–fluoroquinolone; HRZE–regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol; INH–isoniazid; LFX–levofloxacin; LZD–linezolid; MDR-TB–multi-drug resistant TB; MFX–moxifloxacin; Pa–pretomanid; PaMZ–regimen of pretomanid, moxifloxacin, pyrazinamide; PZA–pyrazinamide; ReMOX–regimen of moxifloxacin, rifampicin, pyrazinamide and one of ethambutol or isoniazid; RIF–rifampicin; TB–tuberculosis; TPP–target product profile; WHO–World Health Organization.